- Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results
- Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results
- Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag
- Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene
More ▼
Key statistics
On Friday, Prestige Consumer Healthcare Inc (PBH:NYQ) closed at 68.32, -9.28% below its 52-week high of 75.31, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 66.93 |
---|---|
High | 68.44 |
Low | 66.57 |
Bid | 67.87 |
Offer | 68.63 |
Previous close | 67.32 |
Average volume | 269.39k |
---|---|
Shares outstanding | 49.92m |
Free float | 49.25m |
P/E (TTM) | 16.14 |
Market cap | 3.36bn USD |
EPS (TTM) | 4.17 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:10 BST.
More ▼